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Key Points
•We show that the novel
KCNN4 variant
p.S314P is a gain-of-
function mutation but is
less severe than the
previously reported
p.R352H variant.
• The clinical heteroge-
neity, blurred symp-
toms, and absence of
specific diagnostic





The Gardos channel (hSK4, KCa3.1, KCNN4) was the first ion channel described in human red blood
cells (RBCs), and its physiological function was mainly associated with cell death and volume
homeostasis.1 An adaptive function of the Gardos channel when RBCs pass capillaries or constrictions
has only recently evolved.2-4 Mutations in both the Gardos and the Piezo1 channels reportedly
contribute to hereditary stomatocytosis.5-10
However, differences in clinical features and in RBC properties caused by mutations in these 2 channels
prompt us and others to consider Gardos channelopathy as an independent disease.8-10 In fact, the
majority of KCNN4 variants, falling near the calmodulin-binding site at different residues, lack clear signs
of RBC dehydration, with a normal ektacytometry curve. Only p.V282M/E variants, reported in 2 isolate
families,6,11,12 exhibit clear dehydration with a typical left-shifted ektacytometry curve similar to patients
with PIEZO1 mutations.
Here we present a novel KCNN4 pathogenic variant (p.S314P). We characterized hematologic and
functional parameters of patients from 2 unrelated families carrying this mutation. The intrafamily
variability of clinical presentation, presence of blurred symptoms, and absence of specific diagnostic
markers other than genotyping underline the diagnostic challenge of this disorder.
Case description
We report 2 unrelated Italian families with congenital hemolytic anemia of unknown origin and
heterogeneous clinical presentation.
In family A, the proband (AIII.1) was studied at the age of 3 years for normocytic hemolytic anemia and
received a suspected diagnosis of adenylate kinase deficiency based on enzymatic assay, not fully
confirmed at the molecular level. The father (AII.1) displayed microcytic hemolytic anemia since infancy
and was diagnosed as thalassemic trait due to mutations b39 and deletion a-3.7.
In family B, the proband (BII.2) had a previous diagnosis of hereditary spherocytosis not corrected by
splenectomy; her mother (BI.1) was known to have microcytic anemia since childhood, and her twin
sons were found to have silent hemolytic anemia during a family study at the age of 12 years. Moreover,
a cousin of the proband was referred as being affected by congenital dyserythropoietic anemia type II.
Clinical and hematologic parameters are reported in detail in the supplemental Material.
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Figure 1. A new KCNN4 pathogenic variant and different Osmoscan curves in Gardos channelopathy and PIEZO1 hereditary xerocytosis. (A) Schematic
representation of the KCNN4 gene and functional domains of the protein with the position of the variants associated with Gardos channelopathy. Family trees of family A (Bi)
and family B (Bii); arrows indicate the index cases, light blue represents KCNN4 p.S314P mutation, and gray indicates HBB c.188 C.T, p.Q39X, and a 23.7del variants
corresponding to thalassemic trait. (Ci) Osmoscan curve of patients AIII.1 (red solid line), AII.1 (red dashed line), BI.1 (purple solid line), and BII.2 (purple dashed line),
compared with healthy control subjects (gray area). (Cii) Osmoscan curves of patient AIII.1 carrying the p.S314P variant (red line) and a patient with KCNN4 p.R352H
mutation (green line) compared with healthy control subjects (gray area) and 10 patients carrying missense mutations in the PIEZO1 gene (light blue area).
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Figure 2. Functional tests of the new Gardos channel mutation p.S314P and relation to the mutation p.R325H. (A) Percoll density centrifugation of a blood sample
from patient AIII.1 compared with a control subject. A methodologic description is given in the supplemental Material. (Ai) Image of the centrifuged tubes. (Aii) Profile of the cell
distribution derived from intensity-based analysis of the image shown in panel Aa. Distance zero refers to light cells on top of the tube, and distance 2500 refers to the lowest
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Methods
A targeted next-generation sequencing (NGS) panel containing 40
genes causing hereditary hemolytic anemias was used to identify
the underlying genetic cause in the patients. Ektacytometry
Osmoscan analysis, Percoll gradients, and patch clamp analysis
were performed as previously described.10,13,14 Measurement of
the transmembrane potential was performed by incubating the
RBCs with a proton ionophore in an unbuffered solution, and the pH
value of the suspension was measured as initially introduced by
Macey et al.15
The study was approved by the Ethical Committee of Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan (Area 2-
Milan-N. 606_2013). Detailed methods are given in the supple-
mental Material.
Results and discussion
A new heterozygous KCNN4 variant (NM_002250.2; c.940T.C;
p.S314P) was detected in all the affected cases (Figure 1A-B) by
NGS analysis and confirmed by Sanger sequencing. The mutation
was not previously found in the Genome Aggregation Database
(GnomAD) and 1000 Genomes Projects and was predicted
in silico to be likely pathogenic (pathogenic moderate [PM2],
pathogenetic supporting [PP1 and PP4], following American
College of Medical Genetics and Genomics guidelines).16 It falls
into the calmodulin-binding domain, affecting a highly conserved
residue. NGS analysis did not show other abnormalities that may
justify the clinical phenotype.
RBC deformability and hydration state were assessed by ektacy-
tometry in both families. In all the patients analyzed (AIII.1, AII.1, BI.1,
and B2.II), Osmoscan curves were close to that of healthy control
subjects (Figure 1Ci). The father (AII.1) displayed a slight left shift of
the curve due to the b-thalassemic trait. Patient BII.2 showed
a slight decrease in the maximum elongation index (EImax) and an
increased minimum elongation index (EImin) attributable to the effect
of splenectomy.13
Together, these data suggest that RBC deformability in these
patients was not compromised despite the abnormal morphologic
appearance (Figure 1; supplemental Table 1), similarly to what was
already reported for all the other KCNN4 variants with the exception
of the p.V282M mutation,12 and it was clearly different from that
observed in patients with hereditary stomatocytosis due to PIEZO1
mutations (Figure 1Cii). Additional evidence further confirming the
different nature of these 2 disorders comes from a recent study
comparing clinical features of 6 families with KCNN4mutations and
49 with PIEZO1 mutations. Although the 2 diseases share anemia,
iron overload, and inefficient splenectomy, patients with KCNN4
mutations exhibited more severe hemolysis, with no clear signs
of RBC dehydration and no increased thrombotic risk after
splenectomy.9
The functional assessments as discussed here were performed on
patients AII.1 and AIII.1, with coherent results (family B was not
available for further studies). However, due to the complex genotype
of patient AII.1 (HBB, HBA, and KCNN4 variants), which makes it
difficult to differentiate the effects of single mutations on cellular
properties, results are presented on patient AIII.1.
Percoll density gradient separation revealed a clearly higher density
than control RBCs for all fractions (Figure 2A) and substantially
higher heterogeneity in density. These findings indicate dehydration
of a fraction, but not all cells, and thus an increased Gardos channel
activity in them. Furthermore, Gardos channel activity was directly
evaluated by measuring membrane potential changes induced by
Gardos channel activation using the method of Macey et al15
(Figure 2B) and by measuring whole-cell currents by patch clamp
analysis (Figure 2C). The maximal channel activity was tested after
stimulating the cells with the Ca21-ionophore A23187 in the
presence of 4 mM extracellular Ca21. Figure 2Bi shows that resting
membrane potential and the level of hyperpolarization induced by
full activation of the Gardos channel (and sudden K1-conductance
induced in this way) are not affected in RBCs with the p.S314P
mutation. Nevertheless, the scenario is different when cells are
stimulated with the activator NS30917 (NeuroSearch A/S, Ballerup,
Denmark), which increases the Ca21 sensitivity of the channel.
Figure 2. (continued) measurable position in the tube. Low-density (L), medium-density (M), and high-density (H) fractions are marked with green, dark blue, and red bars,
respectively. (B) Membrane potential measurements in RBC suspensions using the carbonyl cyanide-m-chlorophenylhydrazone method reported by Macey et al.15 A detailed
description is provided in the supplemental Material. (Bi) Within approximately 3 minutes, RBCs reach an equilibrium at the RBC resting membrane potential of 210 mV. When
the Ca21 transporter A23187 at a concentration of 10 mM in the presence of 4 mM Ca21 is added (equivalent to full Gardos channel activation), membrane potential drops
immediately to approximately 280 mV due to the induced K1-conductance. Repolarization is accelerated when 10 mM of the Gardos channel inhibitor TRAM34 is added.
Upon addition of TRITON X-100, which lyses the RBCs, a membrane potential no longer exists (0 mV). Here, mutated cells (KCNN4 p.S314P) react the same as healthy
RBCs. (Bii) Within approximately 3 minutes, added RBCs reach an equilibrium at the RBC resting membrane potential of 210 mV. When 100 mM of the Gardos channel
activator NS309 is added, the membrane potential of the healthy RBCs drops to approximately 215 mV, whereas in the mutated cells, the membrane potential reaches almost
250 mV (p.S314P) and 270 mV (p.R352H), hinting to gain-of-function mutations in both variants. At the end, TRITON X-100 is added to get the 0 mV calibration. Panels Biii
and Biv are experiments performed in analogy to panel Bb but with the addition of 50 mM and 10 mM NS309, respectively. Blue lines represent normal control, green lines
p.S414P mutated cells, and red lines p.R352H KCNN4 variant. (C) Whole-cell recordings of the Gardos channel currents from RBCs of a healthy subject and patient AIII.1
(p.S314P). A detailed methodologic description is presented in the supplemental Material. Currents were elicited by voltage steps from 2130 mV to 50 mV for 500 ms in
20 mV increments at Vh 5 230 mV and recorded in the absence and after application of 1 mM TRAM34, a specific Gardos channel blocker. (Ci) Raw current traces from
a healthy subject’s RBCs in the absence (top left) and in the presence (bottom left) of 1 mM TRAM34 as indicated above the recordings. For comparison, raw current traces
from the patient’s RBCs in the absence (top right) and in the presence (bottom, right) of 1 mM TRAM34 as indicated above the recordings. Note that in this particular example,
the background current in the healthy control subject is higher than in patient AIII.1. (Cii) Comparison of the percent block by 1 mM TRAM34 of the mean currents at 2110 mV
in the healthy and mutated RBCs. Significance was checked based on an unpaired Student t test, *P , .05. (D) Correlation of TRAM34-induced change in current variability
vs NS309-induced membrane potential change for healthy controls and cells with mutations p.S314P and p.R352H. The statistical values are patient based. Values of
p.S314P variant are taken from panels B and C. Patch clamp recordings of p.R352H are from Fermo et al10 (n1 5 23 cells) and 2 additional patients (n2 5 9 cells; n3 5 7
cells). NS309-induced potential changes were measured in three p.R325H patients (exemplified in panel Ca).
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Addition of NS309 (100 mM) leads to a submaximal stimulation of
the Gardos channel with a hyperpolarization similar to that obtained
with A23187. This higher reactivity was observed for all the
concentrations of NS309 tested (10, 50, and 100 mM) (Figure 2Bii-
iv). Indeed, whereas 100 mM of NS309 allows only slight
hyperpolarization development when applied to control cells,
10 mM induces significant hyperpolarization in p.S314P-mutated
cells. Such results indicate that either mutated p.S314P Gardos
channels are intrinsically more sensitive to calcium than normal
channels, or intracellular Ca21 concentration is originally higher in
p.S314P cells compared with control cells, or both.
Figure 2Ci displays representative whole-cell current traces with
500 mM intracellular Ca21 to activate the Gardos channel and after
application of 1 mM TRAM34 to inhibit it. Statistical analysis shows
that the amount of blocked current is higher in the mutated cells
compared with healthy RBCs (Figure 2Cii).
Furthermore, we correlated for healthy control, p.S314P, and
p.R352H (the most common KCNN4 variant, tested on 3 different
patients) the NS309 sensitivity in membrane potential measure-
ments and the current variability in TRAM34-based patch clamp
measurements (Figure 2D). A good correlation (R2 5 0.99) was
observed between 2 different and independent experimental
approaches. All panels of Figure 2 indicate that p.S314P is also
a gain-of-function mutation, although slightly less severe compared
with p.R352H (Figure 2B-D).
Our data enforce the hypothesis that Gardos channelopathy due to
calmodulin-binding site variants differs from PIEZO1 hereditary
xerocytosis in molecular mechanisms and diagnostic features, and
may require differential treatment. Further investigations are re-
quired to elucidate PIEZO1/KCNN4 molecular interactions in cell
volume homeostasis3,18 and in particular the role of the intracellular
calcium.10
Although the complexity of genotype detected in family A may
explain the observed clinical variability, this is not the case in family
B, whose members displayed only the p.S314P KCNN4 variant,
and present clinical phenotypes in line with what was reported in
larger cohorts of patients with KCNN4 mutations.8,9 Despite this, 3
of the 5 affected members received an incorrect diagnosis, and in 2,
anemia was not suspected until 12 years of age, with the possible
consequence of unrecognized iron accumulation in adulthood.
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